Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 spike glycoprotein is a large, trimeric class I fusion protein that decorates the surface of the SARS-CoV-2 virion, giving the virus its characteristic crown-like appearance [UniProt P0DTC2]. It is the primary mediator of viral entry into host cells, consisting of two functional subunits: S1, which contains the receptor-binding domain (RBD) for attachment to angiotensin-converting enzyme 2 (ACE2), and S2, which facilitates the fusion of viral and host cell membranes [Nature, 2020, 583, 7814]. Because of its essential role in the viral life cycle and its accessibility on the viral surface, the spike protein is the principal target for neutralizing antibodies induced by infection or vaccination [NIH, 2021]. Therapeutic interventions, including monoclonal antibodies like Sotrovimab and Bebtelovimab, specifically target epitopes on the spike protein to block ACE2 binding or inhibit the structural transitions required for fusion [FDA, 2022]. However, the protein is subject to significant evolutionary pressure, leading to mutations that can result in immune escape and reduced efficacy of existing therapeutics [PubMed, 34914510].
Neutralization of viral entry by blocking the interaction between the receptor-binding domain (RBD) and the host ACE2 receptor, or by inhibiting the conformational changes required for membrane fusion.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 spike glycoprotein (S protein).